<p>/PRNewswire/ -- 前路易斯安那州檢察長查爾斯·C·福提（Charles C. Foti, Jr.）及其法律事務所 Kahn Swick &amp; Foti, LLC（&#34;KSF&#34;）正在調查 Astria Therapeutics, Inc.（納斯達克代碼：ATXS）擬出售給 BioCryst Pharmaceuticals, Inc.（納斯達克代碼：BCRX）的交易。根據擬議交易的條款，Astria 的股東將為每持有一股 Astria 股票獲得 8.55 美元現金和 0.59 股 BioCryst 普通股。KSF 正在尋求確定這一對價及其形成過程是否合理，或者該對價是否低估了公司。</p>
<p>如果您認為該交易低估了公司，和/或如果您希望討論您關於擬議出售的法律權利，您可以隨時通過電子郵件或撥打 855-768-1857（免費電話）聯繫 KSF 管理合夥人路易斯·S·卡恩（Lewis S. Kahn）（[email protected]），而無需承擔任何義務或費用，或訪問 https://www.ksfcounsel.com/cases/nasdaqgm-atxs/以瞭解更多信息。</p>
<p>要了解更多關於 KSF 的信息，其合夥人包括前路易斯安那州檢察長，請訪問 www.ksfcounsel.com。</p>
<p>Kahn Swick &amp; Foti, LLC</p>
<p>1100 Poydras St., Suite 960</p>
<p>新奧爾良，LA 70163</p>
<p>與我們聯繫：Facebook || Instagram || YouTube || TikTok || LinkedIn</p>
<p>來源 Kahn Swick &amp; Foti, LLC</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA3Jk5ld3NJdGVtSWQ9REE1ODUzNyZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDcxNzEyUFJfTkVXU19VU1BSX19fX19EQTU4NTM3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA3Jk5ld3NJdGVtSWQ9REE1ODUzNyZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDcxNzEyUFJfTkVXU19VU1BSX19fX19EQTU4NTM3"/></p>

BioCryst制藥

ATXS

<p>Kahn Swick & Foti, LLC 正在調查 Astria Therapeutics, Inc. (ATXS) 擬議出售給 BioCryst Pharmaceuticals, Inc. (BCRX) 的事宜。股東將獲得每股 Astria 8.55 美元現金和 0.59 股 BioCryst 股票。該公司旨在確定這一報價是否充分反映了公司的價值。感興趣的各方可以聯繫 KSF 以獲取有關其與此次出售相關的法律權利的更多信息</p>

<p>, /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (&#34;KSF&#34;) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 前路易斯安那州檢察長查爾斯·C·福提（Charles C. Foti, Jr.）及其法律事務所 Kahn Swick &amp; Foti, LLC（&#34;KSF&#34;）正在調查 Astria Therapeutics, Inc.（納斯達克代碼：ATXS）擬出售給 BioCryst Pharmaceuticals, Inc.（納斯達克代碼：BCRX）的交易。根據擬議交易的條款，Astria 的股東將為每持有一股 Astria 股票獲得 8.55 美元現金和 0.59 股 BioCryst 普通股。KSF 正在尋求確定這一對價及其形成過程是否合理，或者該對價是否低估了公司。</p>
</div><p>If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-atxs/ to learn more.</p>
<div class="lb-trans"><p>如果您認為該交易低估了公司，和/或如果您希望討論您關於擬議出售的法律權利，您可以隨時通過電子郵件或撥打 855-768-1857（免費電話）聯繫 KSF 管理合夥人路易斯·S·卡恩（Lewis S. Kahn）（[email protected]），而無需承擔任何義務或費用，或訪問 https://www.ksfcounsel.com/cases/nasdaqgm-atxs/以瞭解更多信息。</p>
</div><p>To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.</p>
<div class="lb-trans"><p>要了解更多關於 KSF 的信息，其合夥人包括前路易斯安那州檢察長，請訪問 www.ksfcounsel.com。</p>
</div><p>Kahn Swick &amp; Foti, LLC</p>
<div class="lb-trans"><p>Kahn Swick &amp; Foti, LLC</p>
</div><p>1100 Poydras St., Suite 960</p>
<div class="lb-trans"><p>1100 Poydras St., Suite 960</p>
</div><p>New Orleans, LA 70163</p>
<div class="lb-trans"><p>新奧爾良，LA 70163</p>
</div><p>CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn</p>
<div class="lb-trans"><p>與我們聯繫：Facebook || Instagram || YouTube || TikTok || LinkedIn</p>
</div><p>SOURCE Kahn Swick &amp; Foti, LLC</p>
<div class="lb-trans"><p>來源 Kahn Swick &amp; Foti, LLC</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA3Jk5ld3NJdGVtSWQ9REE1ODUzNyZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDcxNzEyUFJfTkVXU19VU1BSX19fX19EQTU4NTM3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DA58537&amp;Transmission_Id=202601071712PR_NEWS_USPR_____DA58537&amp;DateId=20260107"/></p>

17:12 ET
			
			
				Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Astria Therapeutics 投資者警報：Kahn Swick & Foti, LLC 正在調查擬議出售 Astria Therapeutics, Inc.的價格和流程是否充分 - ATXS